Louise Frederika Kooij - 09 Sep 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role: Chief Accounting Officer
Signature: /s/ Louise Kooij
Issuer symbol: NAMS
Transactions as of: 09 Sep 2025
Net transactions value: -$2,374,017
Form type: 4
Filing time: 10 Sep 2025, 17:39:03 UTC
Previous filing: 05 Sep 2025
Next filing: 29 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kooij Louise Frederika	Chief Accounting Officer	C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS	/s/ Louise Kooij	10 Sep 2025	0002004379

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NAMS	Ordinary Shares	Options Exercise	$1,500,000	+150,000	+1000%	$10.00	165,000	09 Sep 2025	Direct
transaction	NAMS	Ordinary Shares	Sale	$1,344,062	-53,104	-32%	$25.31	111,896	09 Sep 2025	Direct	F1
transaction	NAMS	Ordinary Shares	Sale	$2,529,955	-96,896	-87%	$26.11	15,000	09 Sep 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAMS	Option (right to buy)	Options Exercise	$0	-150,000	-35%	$0.000000	280,015	09 Sep 2025	Ordinary Shares	150,000	$10.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.87 to $25.86 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.87 to $26.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3	The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.